Try our Advanced Search for more refined results
- Law360
- Law360 UK
- Law360 Pulse
- Law360 Employment Authority
- Law360 Tax Authority
- Law360 Insurance Authority
- Law360 Real Estate Authority
- Law360 Healthcare Authority
- Law360 Bankruptcy Authority
- Products
- Lexis®
- Law360 In-Depth
- Law360 Podcasts
- Rankings
- Regional Powerhouses
- Law360's MVPs
- Women in Law Report
- Law360 400
- Diversity Snapshot
- Practice Groups of the Year
- Rising Stars
- Titans of the Plaintiffs Bar
- Sections
- Adv. Search & Platform Tools
- About all sections
- Browse all sections
- Banking
- Bankruptcy
- Class Action
- Competition
- Employment
- Energy
- Expert Analysis
- Insurance
- Intellectual Property
- Product Liability
- Securities
- Beta Tools
- Track docs
- Track attorneys
- Track judges
(DPP)FWK Holdings, LLC v. Merck & Co., Inc. et al
Case Number:
2:18-cv-00023
Court:
Nature of Suit:
Multi Party Litigation:
Class Action
Judge:
Firms
- DLA Piper
- Gibson Dunn
- Glasser & Glasser
- Goldman Ismail
- Hagens Berman
- Hilliard & Shadowen
- Kaufman & Canoles
- Kessler Topaz
- Lieff Cabraser
- Morgan Lewis
- Sperling & Slater
- Vanek Vickers
Companies
- Cardinal Health Inc.
- Glenmark Pharmaceuticals Ltd.
- H.D. Smith LLC
- McKesson Corp.
- Merck & Co. Inc.
- Supervalu Inc.
- Wegmans Food Markets Inc.
Sectors & Industries:
-
October 18, 2018
Glenmark Moves To Ax Zetia Pay-For-Delay Claims
Glenmark Pharmaceuticals Inc. has asked a Virginia federal judge to nix a suit accusing it of conspiring with Merck & Co. to delay production of a competitor to Merck's cholesterol treatment Zetia, saying that a private settlement with Merck did not prevent the launch of lower-priced alternatives.
-
April 02, 2018
Merck Says Holding Co. Must Arbitrate Pay-For-Delay Claims
Merck & Co. urged a Virginia federal judge on Monday to ax allegations it conspired with generics manufacturer Glenmark Pharmaceuticals Inc. to delay production of a competitor to cholesterol treatment Zetia, saying the suit is subject to an arbitration clause in the company's distribution agreement.
-
January 17, 2018
Merck, Glenmark Stifled Cholesterol Drug Market, Suit Says
Merck & Co. and generics manufacturer Glenmark Pharmaceuticals Inc. were hit with a putative class action in Virginia federal court Wednesday claiming an agreement to keep a generic version of cholesterol treatment Zetia off the market for five years created an unlawful monopoly.